Synthesis, in Silico and Pharmacological Evaluation of New Thiazolidine-4-Carboxylic Acid Derivatives Against Ethanol-Induced Neurodegeneration and Memory Impairment

Shagufta Naz,Lina Tariq Al Kury,Humaira Nadeem,Fawad Ali Shah,Aman Ullah,Rehan Zafar Paracha,Muhammad Imran,Shupeng Li

DOI: https://doi.org/10.2147/jir.s357082

IF: 4.5

2022-01-01

Journal of Inflammation Research

Abstract:[This retracts the article DOI: 10.2147/JIR.S357082.].

What problem does this paper attempt to address?

Synthesis and Biological Evaluation of Benzimidazole Derivatives As Potential Neuroprotective Agents in an Ethanol-Induced Rodent Model

Muhammad Imran,Fawad Ali Shah,Humaira Nadeem,Alam Zeb,Muhammad Faheem,Shagufta Naz,Asma Bukhari,Tahir Ali,Shupeng Li

DOI: https://doi.org/10.1021/acschemneuro.0c00659

2021-01-01

ACS Chemical Neuroscience

Abstract:Alzheimer's disease (AD) is the most devastating and progressive neurodegenerative disease in middle to elder aged people, which can be exacerbated by lifestyle factors. Recent longitudinal studies demonstrated that alcohol consumption exacerbates memory impairments in adults. However, the underlying mechanism of alcohol-induced memory impairment is still elusive. The increased cellular manifestation of reactive oxygen species (ROS) and the production of numerous proinflammatory markers play a critical role in the neurodegeneration and pathogenesis of AD. Therefore, reducing neurodegeneration by decreasing oxidative stress and neuroinflammation may provide a potential therapeutic roadmap for the treatment of AD. In this study, eight new benzimidazole acetamide derivatives (FP1, FP2, FPS-FP10) were synthesized and characterized to investigate its neuroprotective effects in ethanol-induced neurodegeneration in a rat model. Further, three derivatives (FP1, FP7, and FP8) were selected for in vivo molecular analysis based on preliminary in vitro antioxidant screening assay. Molecular docking analysis was performed to assess the affinity of synthesized benzimidazole acetamide derivatives against selected proinflammatory targets (TNF-alpha, IL-6). Biochemical analysis revealed elevated expression of neuroinflammatory markers (TNF-alpha, NF-kappa B, IL-6, NLRP3), increased cellular oxidative stress, and reduced antioxidant enzymes in ethanol-exposed rats brain. Notably, pretreatment with new benzimidazole acetamide derivatives (FP1, FP7, and FP8) significantly modulated the ethanol-induced memory deficits, oxidative stress, and proinflammatory markers (TNF-alpha, NF-kappa B, IL-6, NLRP3) in the cortex. The multipurpose nature of acetamide containing benzimidazole nucleus and its versatile affinity toward numerous receptors highlight its multistep targeting potential. These results indicated the neuroprotective potential of benzimidazole acetamide derivatives (FP1, FP7, and FP8) as novel therapeutic candidates in ethanol-induced neurodegeneration which may partially be due to inhibition of the neuroinflammatory-oxidative stress vicious cycle.
Benzimidazole Containing Acetamide Derivatives Attenuate Neuroinflammation and Oxidative Stress in Ethanol-Induced Neurodegeneration

Muhammad Imran,Lina Tariq Al Kury,Humaira Nadeem,Fawad Ali Shah,Muzaffar Abbas,Shagufta Naz,Arif-ullah Khan,Shupeng Li

DOI: https://doi.org/10.3390/biom10010108

IF: 6.064

2020-01-01

Biomolecules

Abstract:Oxidative stress-induced neuroinflammation is the prominent feature of neurodegenerative disorders, and is characterized by a gradual decline of structure and function of neurons. Many biochemical events emerge thanks to the result of this neurodegeneration, and ultimately provoke neuroinflammation, activation of microglia, and oxidative stress, leading to neuronal death. This cascade not only explains the complexity of events taking place across different stages, but also depicts the need for more effective therapeutic agents. The present study was designed to investigate the neuroprotective effects of newly synthesized benzimidazole containing acetamide derivatives, 3a (2-(4-methoxyanilino)-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl] acetamide) and 3b (2-(Dodecylamino)-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl] acetamide) against ethanol-induced neurodegeneration in the rat model. Both derivatives were characterized spectroscopically by proton NMR (H-1-NMR) and carbon-13 NMR (C-13-NMR) and evaluated for neuroprotective potential using different pharmacological approaches. In vivo experiments demonstrated that ethanol triggered neurodegeneration characterized by impaired antioxidant enzymes and elevated oxidative stress. Furthermore, ethanol administration induced neuroinflammation, as demonstrated by elevated expression of tumor necrotic factor (TNF-alpha), nuclear factor kappa B (NF-kappa B), cyclooxygenase-2 (COX2), and ionized calcium-binding adapter molecule-1 (Iba-1), which was further validated by enzyme-linked immunosorbent assay (ELISA). Treatment with 3a and 3b ameliorated the ethanol-induced oxidative stress, neuroinflammation, and memory impairment. The affinity of synthesized derivatives towards various receptors involved in neurodegeneration was assessed through docking analysis. The versatile nature of benzimidazole nucleus and its affinity toward several receptors suggested that it could be a multistep targeting neuroprotectant. As repetitive clinical trials of neuroprotectants targeting a single step of the pathological process have failed previously, our results suggested that a neuroprotective strategy of acting at different stages may be more advantageous to intervene in the vicious cycles of neuroinflammation.
Retraction of "Toxicological Screening of 4-Phenyl-3,4-dihydrobenzo[ h]quinolin-2(1 H)-one: A New Potential Candidate for Alzheimer's Treatment"

Fareeha Anwar,Uzma Saleem,Atta Ur Rehman,Bashir Ahmad,Tariq Ismail,Muhammad Usman Mirza,Lee Yean Kee,Iskandar Abdullah,Sarfraz Ahmad

DOI: https://doi.org/10.1021/acsomega.4c08066

IF: 4.1

2024-09-06

ACS Omega

Abstract:[This retracts the article DOI: 10.1021/acsomega.1c00654.].
Design, Synthesis and Evaluation of Novel Chloro- Oxime Derivatives for Neurodegenerative Diseases

Aijun Zhang,Pengfei Fu,Zaijun Zhang,Haiyun Chen,Pei Yu

2016-01-01

Abstract:Neurodegenerative disease is a fatal disease of the human nervous system, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and related polyglutamine expansion diseases. The US FDA had approved several drugs to treat neurodegenerative diseases, however, almost none of them could delay progress of these diseases and offer cure. A key molecular pathway implicated in neurodegenerative diseases is the misfolding aggregation and accumulation of proteins in neurons. Chloro-oxime derivatives, such as bimoclomol and arimoclomol, promote the expression of heat shock proteins and improve the abilities of normal protein folding and degrade misfolded proteins. Based on the structure of bimoclomol and arimoclomol, we substituted the pyridine and piperazine by TMP and other amino groups, and synthesised a series of novel chloro-oxime derivatives. Among these chloro-oxime derivatives, compounds 9b and 13b were demonstrated to be neuroprotective against MG-132-induced neurotoxicity in SH-SY5Y cells.
Correction: Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurodegenerative disease treatment

Feba Benny,Jong Min Oh,Sunil Kumar,Mohamed A. Abdelgawad,Mohammed M. Ghoneim,Mohamed Sadek Abdel-Bakky,Neelima Kukerti,Jobin Jose,Hoon Kim,Bijo Mathew

DOI: https://doi.org/10.1039/d3ra90123h

IF: 4.036

2024-01-01

RSC Advances

Abstract:Correction for ‘Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurodegenerative disease treatment’ by Feba Benny et al. , RSC Adv. , 2023, 13 , 35240–35250, https://doi.org/10.1039/D3RA07035B.

chemistry, multidisciplinary
Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Norifumi Shioda,Yui Yamamoto,Feng Han,Shigeki Moriguchi,Kohji Fukunaga

DOI: https://doi.org/10.1002/chin.201143267

2011-01-01

ChemInform

Abstract:Loss of cholinergic neurons and/or dysfunction of the glutamatergic system in the central nervous system cause learning impairment in experimental Alzheimer's (Alz) disease animals and Alz patients. Furthermore, the impaired cholinergic system is likely implicated in depressive behaviors in Alz patients. Neurogenesis persistently occurs in the forebrain subventricular zone (SVZ) and hippocampal subgranular zone (SGZ) in rodent and human brains. Notably, impaired neurogenesis in those regions is implicated not only in memory deficits but also in depressive behaviors. We have recently found that olfactory bulbectomized (OBX) mice reveal memory impairment and depressive behaviors. Using this attractive OBX mice model, we discovered a novel cognitive enhancer, spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101), that is a new azaindolizinone derivative without inhibitory action on acetylcholine esterase (AChE). Interestingly, ZSET1446 improved learning and memory by potentiating nicotine-induced ACh release in the hippocampus of amyloid-beta infused rats. In addition, ZSET1446 restored OBX-induced cognitive deficits in mice. Furthermore, chronic ZSET1446 administration significantly rescues decreased neuronal precursor cell proliferation seen in the dentate gyrus of OBX mice. Consistent with enhanced neurogenesis, chronic ZSET1446 administration improved depressive behavior assessed using the tail suspension test in OBX mice. Protein kinase B (Akt) and extracellular signal-regulated kinase pathways likely mediate ZSET1446-induced neurogenesis. These results suggest that ZSET1446 action via stimulation of the cholinergic system elicits improvement of the depression and cognitive impairment observed in Alz disease patients.
Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Zhi-pei Sang,Xiao-ming Qiang,Yan Li,Bei Wu,Hui Zhang,Ming-gao Zhao,Yong Deng

DOI: https://doi.org/10.1111/cbdd.12580

2015-01-01

Chemical Biology & Drug Design

Abstract:A series of scutellarein carbamate derivatives were designed and synthesized based on the multitarget‐directed drug design strategy for treatment of Alzheimer's disease. Their acetylcholinesterase and butyrylcholinesterase inhibitory activities, antioxidant activities, metals chelation, and neuroprotective effects against hydrogen peroxide‐induced PC12 cell injury were evaluated in vitro. The preliminary results indicated that compound 7b exhibited good inhibitory potency toward AChE and BuChE with IC50 values of 1.2 ± 0.03 μm and 22.1 ± 0.15 μm, respectively, possessed the strong antioxidant potency (10.3 trolox equivalents), as well as acted as a selective metal chelator and neuroprotective agent. Furthermore, 7b could improve memory impairment induced by scopolamine, ethanol, and sodium nitrite using the step‐down passive avoidance task in vivo and could remarkably decrease the activity of acetylcholinesterase in mice brain. This study indicated that 7b could be considered as a potential multitarget agent against AD.
Synthesis, Biological Evaluation, Molecular Docking and Dynamic Simulation of Novel Benzofuran Derivatives As Potential Agents Against Alzheimer's Disease

Muhammad Shahid Nadeem,Shawkat Hayat,Fazal Rahim,Jalaluddin Azam Khan,Hayat Ullah,Muhammad Taha,Gaurav Gupta,Abdul Wadood,Syed Adnan Ali Shah,Imran Kazmi,Saima Iftikhar,Khushi Muhammad

DOI: https://doi.org/10.1016/j.molstruc.2024.140279

IF: 3.841

2025-01-01

Journal of Molecular Structure

Abstract:We have synthesized novel benzofuran derivatives (1-20), 1-20 ), characterized through different spectroscopic techniques such as 1 HNMR, 13 CNMR, HREI-MS and screened against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes. All derivatives showed inhibitory activities having IC50 50 values ranging from 0.70 f 0.01 to 28.10 f 0.50 mu M (against AChE), while 0.80 f 0.01 to 31.20 f 0.60 mu M (against BuChE) as compared to the standard drug Donepezil (IC50 50 = 2.16 f 0.12 and 4.50 f 0.10 mu M, respectively). Except derivative 5, all other derivatives of the series showed good inhibitory activity against both acetylcholinesterase and butyrylcholinesterase, but some analogues like 2, 4, 7, 14, 15, and 16 displayed many folds better inhibitory activity than the standard drug donepezil. The influences of substituents on inhibitory activity were superficially resonated via the structure-activity relationship. We established molecular docking and MD simulation studies to confirm the binding interaction between potent derivatives and active sites of enzymes.
WITHDRAWN: Design and Synthesis of Pivalic Acid Linked Tacrine-No Donor Hybrids As Novel Anti-Alzheimer Drug Candidates.

Lei Fang,Carolin Roegler,Michael Decker,Yihua Zhang,Jochen Lehmann

DOI: https://doi.org/10.1016/j.bmcl.2009.06.089

IF: 2.94

2009-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Synthesis, Characterization and Biological Evaluation of Benzothiazole-Isoquinoline Derivative

Weihua Liu,Donghai Zhao,Zhiwen He,Yiming Hu,Yuxia Zhu,Lingjian Zhang,Lianhai Jin,Liping Guan,Sihong Wang

DOI: https://doi.org/10.3390/molecules27249062

IF: 4.6

2022-12-19

Molecules

Abstract:Currently, no suitable clinical drugs are available for patients with neurodegenerative diseases complicated by depression. Based on a fusion technique to create effective multi-target-directed ligands (MTDLs), we synthesized a series of (R)-N-(benzo[d]thiazol-2-yl)-2-(1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl) acetamides with substituted benzothiazoles and (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline. All compounds were tested for their inhibitory potency against monoamine oxidase (MAO) and cholinesterase (ChE) by in vitro enzyme activity assays, and further tested for their specific inhibitory potency against monoamine oxidase B (MAO-B) and butyrylcholinesterase (BuChE). Among them, six compounds (4b-4d, 4f, 4g and 4i) displayed excellent activity. The classical antidepressant forced swim test (FST) was used to verify the in vitro results, revealing that six compounds reduced the immobility time significantly, especially compound 4g. The cytotoxicity of the compounds was assessed by the MTT method and Acridine Orange (AO) staining, with cell viability found to be above 90% at effective compound concentrations, and not toxic to L929 cells reversibility, kinetics and molecular docking studies were also performed using compound 4g, which showed the highest MAO-B and BuChE inhibitory activities. The results of these studies showed that compound 4g binds to the primary interaction sites of both enzymes and has good blood-brain barrier (BBB) penetration. This study provides new strategies for future research on neurodegenerative diseases complicated by depression.
Design, synthesis and biological evaluation of pyranocarbazole derivatives against Alzheimer’s disease, with antioxidant, neuroprotective and cognition enhancing properties

Yingda Zang,Jingwen Ning,Ke Liu,Meiyu Shang,Caixia Zang,Chuangjun Li,Jie Ma,Xinyi Chen,Jingwei Ma,Gen Li,Yang Yang,Xiuqi Bao,Dan Zhang,Dongming Zhang

DOI: https://doi.org/10.1016/j.bioorg.2022.106179

IF: 5.307

2022-12-01

Bioorganic Chemistry

Abstract:A series of novel pyranocarbazole alkaloids were designed and synthesized as derivatives of Claulansine F and CZ-7. Some of the compounds showed strong neuroprotective effects and anti-lipid peroxidation capacity. Among these compounds, 10b, introduced leucine at the C-3 position of pyranocarbazole, was the most active in inhibiting the programmed death of SH-SY5Y cells. This compound exhibited stronger free radical scavenging activity than Edaravone. Furthermore, 10b could penetrate the blood-brain barrier (BBB). More importantly, 10b showed a tendency of improvement in learning and memory in the dose range of 10-40 mg/kg. The research on mechanisms indicated that 10b could reduce oxidative stress in the brain of Aβ<sub>25-35</sub>-intoxicated mice, and then improve the cognitive function of Aβ<sub>25-35</sub>-intoxicated mice. Our findings suggest that 10b may be promising for further evaluation as an intervention for Alzheimer's Disease.

biochemistry & molecular biology,chemistry, organic
Synthesis, biological and computational evaluation of benzoxazole hybrid analogs as potential anti-Alzheimer's agents

Mohamed S Othman,Rafaqat Hussain,Fazal Rahim,Hayat Ullah,Shoaib Khan,Muhammad Taha,Mohamed A Fareid,Anas T Altaleb,Shimaa M Aboelnaga,Syed Adnan Ali Shah

DOI: https://doi.org/10.1080/17568919.2024.2393569

Abstract:Aim: Current study aims exploration of bis-benzoxazole bearing bis-Schiff base scaffolds (1-16) as anti-Alzheimer's agents.Materials & methods: 2-aminophenol is used as starting materials which react with different reagents in different step to give us bis-benzoxazole bearing bis-Schiff base analogs. NMR and HREI-MS techniques were used for characterization. All derivatives demonstrated varied range of activities with IC50 values 1.10 ± 0.40-24.50 ± 0.90 μM against acetylcholinesterase (AChE) and 1.90 ± 0.70-28.60 ± 0.60 μM against butyrylcholinesterase (BuChE) in contrast to donepezil. In both cases, analog-3 was found most potent. Molecular docking explored modes of interactions between scaffolds and receptor sites of targeted enzymes.Conclusion: This study offering promising approach for optimization and development of potent inhibitors of cholinesterase enzymes.
Synthesis and biological evaluation of a new class of benzothiazines as neuroprotective agents

Alessandra Mancini,Alessia Chelini,Angela Di Capua,Loretta Castelli,Simone Brogi,Marco Paolino,Germano Giuliani,Andrea Cappelli,Maria Frosini,Lorenzo Ricci,Erminia Leonelli,Gianluca Giorgi,Antonio Giordani,Jacopo Magistretti,Maurizio Anzini

DOI: https://doi.org/10.1016/j.ejmech.2016.11.053

2017-01-27

Abstract:Neurodegenerative diseases are disorders related to the degeneration of central neurons that gradually lead to various, severe alterations of cognitive and/or motor functions. Currently, for no such diseases does any pharmacological treatment exist able to arrest its progression. Riluzole (1) is a small molecule able to interfere with multiple cellular and molecular mechanisms of neurodegeneration, and is the only approved treatment of amyotrophic lateral sclerosis (ALS), the progression of which proved to significantly slow, thus increasing somewhat average survival. Here we report the synthesis of differently functionalized 4H-3,1-benzothiazine (5-6) and 2H-1,4-benzothiazine (7) series as superior homologues of 1. Biological evaluation demonstrated that amidine 4H-3,1-benzothiazine derivatives 5b-d can reduce glutamate and LDH release in the oxygen/glucose deprivation and reperfusion model (OGD/R) applied to brain slices with a higher potency than 1. Moreover the mentioned compounds significantly reduce glutamate- and 6-hydroxydopamine (6-OHDA)-induced cytotoxicity in neuroblastoma cells. In addition, the same compounds limit ROS formation in both neuronal preparations. Finally, 5c proved effective in inhibiting neuronal voltage-dependent Na+ and Ca2+-channels, showing a profile comparable with that of 1.
Synthesis and Neurobehavioral Evaluation of a Potent Multitargeted Inhibitor for the Treatment of Alzheimer's Disease

Mohd Shahnawaz Khan,Zuber Khan,Nasimudeen R Jabir,Sidharth Mehan,Mohd Suhail,Syed Kashif Zaidi,Torki A Zughaibi,Mohammad Abid,Shams Tabrez

DOI: https://doi.org/10.1007/s12035-024-04351-w

2024-07-15

Abstract:Alzheimer's disease (AD) poses a significant health challenge worldwide, affecting millions of individuals, and projected to increase further as the global population ages. Current pharmacological interventions primarily target acetylcholine deficiency and amyloid plaque formation, but offer limited efficacy and are often associated with adverse effects. Given the multifactorial nature of AD, there is a critical need for novel therapeutic approaches that simultaneously target multiple pathological pathways. Targeting key enzymes involved in AD pathophysiology, such as acetylcholinesterase, butyrylcholinesterase, beta-site APP cleaving enzyme 1 (BACE1), and gamma-secretase, is a potential strategy to mitigate disease progression. To this end, our research group has conducted comprehensive in silico screening to identify some lead compounds, including IQ6 (SSZ), capable of simultaneously inhibiting the enzymes mentioned above. Building upon this foundation, we synthesized SSZ, a novel multitargeted ligand/inhibitor to address various pathological mechanisms underlying AD. Chemically, SSZ exhibits pharmacological properties conducive to AD treatment, featuring pyrrolopyridine and N-cyclohexyl groups. Preclinical experimental evaluation of SSZ in AD rat model showed promising results, with notable improvements in behavioral and cognitive parameters. Specifically, SSZ treatment enhanced locomotor activity, ameliorated gait abnormalities, and improved cognitive function compared to untreated AD rats. Furthermore, brain morphological analysis demonstrated the neuroprotective effects of SSZ, attenuating Aβ-induced neuronal damage and preserving brain morphology. Combined treatment of SSZ and conventional drugs (DON and MEM) showed synergistic effects, suggesting a potential therapeutic strategy for AD management. Overall, our study highlights the efficacy of multitargeted ligands like SSZ in combating AD by addressing the complex etiology of the disease. Further research is needed to elucidate the full therapeutic potential of SSZ and the exploration of similar compounds in clinical settings, offering hope for an effective AD treatment in the future.
Insight from molecular modeling and ADMET analysis: Design, synthesis and in vitro acetylcholinesterase and butyrylcholinesterase assessment of thiazolidinone containing benzoxazole hybrids derivatives

Rafaqat Hussain,Muhammad Irfan Afridi,Shoaib Khan,Yousaf Khan,Tayyiaba Iqbal,Liaqat Rasheed,Mohammad Shahidul Islam,Kholood A. Dahlous

DOI: https://doi.org/10.1016/j.molstruc.2024.140589

IF: 3.841

2024-11-11

Journal of Molecular Structure

Abstract:Alzheimer's disease (AD) is a brain disorder medically defined as loss of memory and analytical reasoning abilities of an infected person. The adult or aged peoples are more likely to be adversely affected by this disease. Following this prospect, this study is conducted to synthesize a novel class of (Z)-2-(((Z)-2-(benzo[d]oxazol-2-ylthio)-1-phenylethylidene)hydrazono)-3-phenylthiazolidin-4-one based derivatives and evaluate its performance towards the treatment of AD. This study showed the better results when compared to the inhibition potential of the standard drug Donepezil against AChE (IC 50 = 4.10 ± 1.05 μM) and against BuChE (IC 50 =6.59 ± 1.63 μM), the inhibition potential shown by benzimidazole based thiadiazole scaffolds against the targeted enzymes is of wide range. The inhibition potential of all the scaffolds against AChE ranged from 2.89 ± 0.65 μM to 19.04 ± 0.49 μM and against BuChE ranged from 3.70 ± 0.98 μM to 23.19 ± 0.71 μM. Moreover, to investigate the binding interaction of effective scaffolds against the active sites of AChE and BuChE, molecular docking studies were carried out and the analysis data evaluated the substantial binding interaction of scaffolds against the targeted enzymes. The structural characteristic of each scaffold is determined by using different spectroscopic techniques. In this work only three analogues found to be the most active having the observed IC 50 values 7d, 3.05 ± 0.19 μM, 2.90 ± 0.87 μM(for BuChE), 7g, 3.88 ± 0.32 μM(for AChE), 4.98 ± 0.54 μM(for BuChE), 7k 2.89 ± 0.65 μM(for AChE), 3.70 ± 0.98 μM(for BuChE). Furthermore, the selected analogues considered for In-Vivo and cytotoxic study as well as structure modification carried out in search of more active analogues.

chemistry, physical
New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics

Eman M Azmy,Ibrahim F Nassar,Mohamed Hagras,Iten M Fawzy,Maghawry Hegazy,Mahmoud Mohamed Mokhtar,Amr Mohamed Yehia,Nasser Sm Ismail,Walaa H Lashin

DOI: https://doi.org/10.4155/fmc-2022-0228

Abstract:Background: Alzheimer's disease is a neurological disorder that causes brain cells to shrink and die. Aim: Thirteen novel 'oxathiolanyl', 'pyrazolyl' and 'pyrimidinyl' indole derivatives were designed and synthesized as anti-Alzheimer's disease treatment. Method: In vitro enzyme assay was performed against both AChE and BChE enzymes. In addition, antioxidant assay and cytotoxicity on a normal cell line were determined. Molecular docking and dynamic simulations were conducted to confirm the binding mode in both esterases' active sites. In silico absorption, distribution, metabolism, excretion and toxicity studies were also carried out. Results & conclusion: Compounds 5, 7 and 11 exhibited superior inhibitory activity against acetylcholinesterase and butyrylcholinesterase, with IC50 values of 0.042 and 3.003 μM, 2.54 and 0.207 μM and 0.052 and 2.529 μM, respectively, compared with donepezil.
Design, synthesis and evaluation of aminothiazole derivatives as potential anti-Alzheimer's candidates

Arti Soni,Ashwani Kumar,Vivek Kumar,Ravi Rawat,Volkan Eyupoglu

DOI: https://doi.org/10.4155/fmc-2023-0290

2024-02-22

Future Medicinal Chemistry

Abstract:Aim: The objective of the present study was to design, synthesize and evaluate diverse Schiff bases and thiazolidin-4-one derivatives of aminothiazole as key pharmacophores possessing acetylcholinesterase inhibitory activity. Materials & methods: Two series of compounds (13 each) were synthesized and evaluated for their acetylcholinesterase inhibition and antioxidant activity. Molecular docking of all compounds was performed to provide an insight into their binding interactions. Results: Compounds 2j (IC 50 = 0.03 μM) and 3e (IC 50 = 1.58 μM) were found to be the best acetylcholinesterase inhibitors among compounds of their respective series. Molecular docking analysis supported the results of in vitro activity by displaying good docking scores with the binding pocket of human acetylcholinesterase (Protein Data Bank ID: 4EY7). Conclusion: Compound 2j emerged as a potential lead compound with excellent acetylcholinesterase inhibition, antioxidant and chelation activity.

chemistry, medicinal
Corrigendum to “tanshinone IIA Alleviates CCL2-Induced Leaning Memory and Cognition Impairment in Rats: A Potential Therapeutic Approach for HIV-Associated Neurocognitive Disorder”

Yuan-jun Liao,Jian-min Chen,Jiang-yi Long,Yi-jun Zhou,Bing-yu Liang,Yan Zhou

DOI: https://doi.org/10.1155/2020/5834542

2020-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2020/2702175.].
Design, Synthesis and Biological Evaluation of Novel (e)‐hydroxystyryl Aralkyl Sulfones As Neuroprotective Agents

Ying Chen,Yameng Hao,Qian Liu,Bolin Wu,Yunqi Liu,Zhili Zhang,Chao Tian,Xianling Ning,Ying Guo,Xiaowei Wang,Junyi Liu

DOI: https://doi.org/10.1002/slct.202001401

2020-01-01

ChemistrySelect

Abstract:A novel class of (E)-hydroxystyryl aralkyl sulfones were designed and synthesized as neuroprotective agents. Their neuroprotective properties were assessed by several antioxidant models including 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals scavenging model, neuronal protective effects against neurotoxins such as hydrogen peroxide (H2O2), 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium iodide (MPP+). Besides, the anti-inflammatory activity was evaluated by lipopolysaccharide (LPS)-induced nitric oxide (NO) release model in BV2 microglial cells. The result demonstrated that cinnamyl substituted compound5 hexhibited prominent antioxidant activity in H(2)O(2)and 6-OHDA models and higher anti-inflammatory potency (IC50=7.3 mu M) than lead compound1(IC50=13.4 mu M). Furthermore, compound5 hdisplayed predicted CNS (+) blood-brain barrier permeability (P-e=5.66x10(-6) cm s(-1)) in PAMPA model and low toxicity in PC12 and BV2 cells. These multifunctional properties highlight compound5 his a promising candidate for further development against neurodegenerative diseases.
Insight into role of triazole derived Schiff base bearing sulfonamide derivatives in targeting Alzheimer's disease: Synthesis, characterization, in vitro and in silico assessment

Shoaib Khan,Rafaqat Hussain,Yousaf Khan,Tayyiaba Iqbal,Muhammad Bilal Khan,Khairia Mohammed Al-Ahmary,Saedah R. Al Mhyawi

DOI: https://doi.org/10.1016/j.molstruc.2024.138845

IF: 3.841

2024-06-04

Journal of Molecular Structure

Abstract:Alzheimer's disease (AD), a chronic neurodegenerative disorder is reported with its high prevalence and increasing at a disturbing level across the world. Due to no availability of therapeutic drugs permanently treating AD, it became imperative to develop potent therapeutic anti-Alzheimer's agent with spellbinding efficacy and minimal side effects. With this objective, herein current study we had efficiently synthesized a novel library of triazole derived Schiff base bearing sulfonamide scaffolds ( 1-16 ). The in vitro efficacy of these compounds as anti-Alzheimer was evaluated in contrast to Donepezil (IC 50 = 5.10 ± 0.20 μM, 5.70 ± 0.30 μM for AChE BuChE, respectively). These synthesized compounds displayed moderate to excellent inhibition potential with inhibitory concentration ranging between 1.90 ± 0.40 μM to 14.50 ± 0.20 μM against AChE and 2.10 ± 0.10 μM to 14.80 ± 0.40 μM against BuChE. Among the synthesized compounds, analog 4 (IC 50 =1.90 ± 0.40 μM and 2.10 ± 0.10 μM) having –CF 3 at para -position exhibited promising biological potency. For structural confirmation of these compounds HREI-MS and 1 HNMR, 13 CNMR techniques were employed. The binding affinity of all the lead candidates with different amino acids of targeted enzymes was studied in silico under molecular docking. Moreover, ADMET analysis was also conducted to predict the drug likeness characteristics of all the active compounds.

chemistry, physical

Synthesis, in Silico and Pharmacological Evaluation of New Thiazolidine-4-Carboxylic Acid Derivatives Against Ethanol-Induced Neurodegeneration and Memory Impairment

Synthesis and Biological Evaluation of Benzimidazole Derivatives As Potential Neuroprotective Agents in an Ethanol-Induced Rodent Model

Benzimidazole Containing Acetamide Derivatives Attenuate Neuroinflammation and Oxidative Stress in Ethanol-Induced Neurodegeneration

Retraction of "Toxicological Screening of 4-Phenyl-3,4-dihydrobenzo[ h]quinolin-2(1 H)-one: A New Potential Candidate for Alzheimer's Treatment"

Design, Synthesis and Evaluation of Novel Chloro- Oxime Derivatives for Neurodegenerative Diseases

Correction: Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurodegenerative disease treatment

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Synthesis, Biological Evaluation, Molecular Docking and Dynamic Simulation of Novel Benzofuran Derivatives As Potential Agents Against Alzheimer's Disease

WITHDRAWN: Design and Synthesis of Pivalic Acid Linked Tacrine-No Donor Hybrids As Novel Anti-Alzheimer Drug Candidates.

Synthesis, Characterization and Biological Evaluation of Benzothiazole-Isoquinoline Derivative

Design, synthesis and biological evaluation of pyranocarbazole derivatives against Alzheimer’s disease, with antioxidant, neuroprotective and cognition enhancing properties

Synthesis, biological and computational evaluation of benzoxazole hybrid analogs as potential anti-Alzheimer's agents

Synthesis and biological evaluation of a new class of benzothiazines as neuroprotective agents

Synthesis and Neurobehavioral Evaluation of a Potent Multitargeted Inhibitor for the Treatment of Alzheimer's Disease

Insight from molecular modeling and ADMET analysis: Design, synthesis and in vitro acetylcholinesterase and butyrylcholinesterase assessment of thiazolidinone containing benzoxazole hybrids derivatives

New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics

Design, synthesis and evaluation of aminothiazole derivatives as potential anti-Alzheimer's candidates

Corrigendum to “tanshinone IIA Alleviates CCL2-Induced Leaning Memory and Cognition Impairment in Rats: A Potential Therapeutic Approach for HIV-Associated Neurocognitive Disorder”

Design, Synthesis and Biological Evaluation of Novel (e)‐hydroxystyryl Aralkyl Sulfones As Neuroprotective Agents

Insight into role of triazole derived Schiff base bearing sulfonamide derivatives in targeting Alzheimer's disease: Synthesis, characterization, in vitro and in silico assessment